Endo International (ENDP) Got Some Good News

Canaccord Genuity analyst Dewey Steadman upgraded Endo International (ENDP) to Buy today and set a price target of $20. The company’s shares closed yesterday at $13.19.

According to, Steadman is a 1-star analyst with an average return of -2.4% and a 34.2% success rate. Steadman covers the Healthcare sector, focusing on stocks such as Amneal Pharmaceuticals Inc, ANI Pharmaceuticals Inc, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Endo International is a Moderate Buy with an average price target of $17.56.

See today’s analyst top recommended stocks >>

The company has a one-year high of $18.50 and a one-year low of $5.27. Currently, Endo International has an average volume of 4.47M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The company operates through the following segments: U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals and International Pharmaceuticals.